pdufa.bio

KEYTRUDA QLEX

Page updated ·next FDA decision on the calendar ·Data as of Oct 11, 2026 9:31 PM ET

KEYTRUDA QLEX The FDA approved it on Sep 19, 2025. 1 FDA decision on record below. Every date links its source.

MRK catalyst hub

All upcoming FDA decision dates on the 2026 PDUFA calendar

About this program

We track 1 catalyst event for this program: 0 upcoming and 1 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.

Catalyst history

FDA decision · Sep 19, 2025 ✓ ApprovedMRK

Specialist biotech funds holding MRK, 13F for the quarter ended June 30, 2026

FundSharesValue at quarter endFiling
OrbiMed Advisors663,400$85.2 millionfiled August 14, 2026

13F reports list long positions in common stock at quarter end, are due 45 days later, and show no short positions or later trades. Notes, warrants and other instruments are not counted as shares.

Questions

When is KEYTRUDA QLEX's next FDA decision or readout?

No upcoming catalyst is on our calendar for KEYTRUDA QLEX; 1 FDA decision is on record below.

What happened at KEYTRUDA QLEX's most recent FDA decision?

On Sep 19, 2025 the FDA approved the application. The decision page carries the source document and the measured share-price reaction.

Has KEYTRUDA QLEX been approved by the FDA?

Yes. The FDA approved an application for KEYTRUDA QLEX on Sep 19, 2025; the decision page linked above carries the source.

Where does this data come from?

FDA announcements, sponsor press releases and SEC filings; every date on this page links its source.